Process for modifying drug crystal formation

Details for Australian Patent Application No. 2004206731 (hide)

Owner Novartis AG

Inventors Wieckhusen, Dierk; Pfeffer, Sabine

Agent Davies Collison Cave

Pub. Number AU-B-2004206731

PCT Pub. Number WO2004/064806

Priority 0301259.8 20.01.03 GB

Filing date 19 January 2004

Wipo publication date 5 August 2004

Acceptance publication date 20 March 2008

International Classifications

A61K 9/14 (2006.01) Medicinal preparations characterised by special physical form - Particulate form, e.g. powders

A61K 9/28 (2006.01) Medicinal preparations characterised by special physical form - Dragees

C07D 307/88 (2006.01) Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom

Event Publications

28 July 2005 PCT application entered the National Phase

  PCT publication WO2004/064806 Priority application(s): WO2004/064806

11 August 2005 Corrigenda

  PCT applications that have entered the National Phase - Name Index Under the name Novartis Pharma GmbH, Application No. 2004206731, under INID (71) correct the name to read Novartis AG.

20 March 2008 Application Accepted

  Published as AU-B-2004206731

17 July 2008 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004206734-Disposable defibrillator electrode assembly

2004206728-Hip prosthesis comprising a shaft to be inserted into the femur